Medical/Pharmaceuticals

MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia

SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 inAustralia, a self-developed oral antibacterial agent in development for the treatment of nontuberculous mycoba...

2024-10-25 19:29 1293

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

NANJING, China, Oct. 25, 2024 /PRNewswire/ -- On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th World Stroke Conference (WSC): brain cell protection combined with edaravone ...

2024-10-25 15:14 1125

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...

2024-10-24 20:00 1133

SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...

2024-10-24 20:00 825

Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights

PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter challenges like safety assessments, cost control, and te...

2024-10-24 17:53 861

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cance...

2024-10-24 12:42 1433

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held inBarcelona, Spain, from October 23-25, 2024. The ...

2024-10-24 10:45 1362

Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance

* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading environment while maintaining or improving screening quality, and predicts cancer risk up to six years in advance SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- Amid rising demands and a global shor...

2024-10-23 21:00 1744

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-cultured vaccines. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience, a ...

2024-10-23 20:00 1607

Doceree forms Strategic Partnership with The Ward Marketing Group to Strengthen Its Global Footprint; Expands into Australian Market

Expanding its reach from 22 markets to include Australia, Doceree partners with The Ward Marketing Group to enhance HCP-patient engagement in the region through innovative marketing solutions. SYDNEY, Oct. 23, 2024 /PRNewswire/ -- Doceree, the world's first global network of physician-only platf...

2024-10-23 19:05 1363

Samsung Biologics reports third quarter 2024 financial results

* Recorded Q3'24 consolidated revenue of KRW 1.2 trillion * Recorded Q3'24 consolidated operating profit of KRW 338.6 billion * Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea, Oct. 23, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 2079...

2024-10-23 14:55 1099

Minghui Pharmaceutical Inc. Announces Positive Topline Results from Phase Ib/II Clinical Trial of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Patients with Active, Moderate-to-Severe Thyroid Eye Disease (TED)

SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its Phase Ib/II clinical trial of MHB018A in patients with active...

2024-10-22 18:00 4616

HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure

NANJING, China, Oct. 22, 2024 /PRNewswire/ -- HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company,today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for "Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) a...

2024-10-22 13:47 985

South Korean Mental Tech Startup DoctorPresso Publishes Study to Detect Depression from User-Generated Diary test data in International Journal

SEOUL, South Korea, Oct. 21, 2024 /PRNewswire/ -- Doctorpresso's study to detect depression from user-generated diary text data was published in the September 2024 issue of the Journal of Medical Internet Research (JMIR) in recognition of its excellence. JMIR noted the "new approach of Doctorpress...

2024-10-22 09:08 1782

A Comprehensive Introduction of the oneClick+ antigen platform

SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to help tumor immunotherapy research and development. oneClick+ antigen platform is designed to provide high-quality annotation-related protein seque...

2024-10-22 03:00 1233

Datasea Announces the Closing of a $4.0 Million Private Offering, Primarily Funded by the Company's CEO and Director

BEIJING, Oct. 21, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based digital technology company focused on innovative high-tech acoustics and 5G AI multimodal digital technology, today announced that, as ofOctober 15, 2024, the Company closed its Regulati...

2024-10-21 21:30 2309

Mediso introduces true theranostic TheraMAX SPECT/CT

HAMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European Association of Nuclear Medicine (EANM). The first global installation of the A...

2024-10-21 16:00 1002

Great Bay Bio Intelligent Drug Development Ecosystem Officially Launched

HONG KONG, Oct. 20, 2024 /PRNewswire/ -- On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB announced the of...

2024-10-21 13:57 989

MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum

SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future tre...

2024-10-18 22:09 1257

Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.

- Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer's disease treatments such as 'Leqembi' and 'Kisunla' SEOUL, South Korea, Oct. 18, 2024 /P...

2024-10-18 21:00 2533
12345678 ... 213